Oral Abstracts
O1 Functionally distinct HMGB1 isoforms correlate with physiological processes in drug-induced SJS/TEN
Daniel F. Carr1, Wen-Hung Chung2, Rosalind E. Jenkiins1, Mas Chaponda1, Gospel Nwikue1, Elena M. Cornejo Castro1, Daniel J. Antoine1, Munir Pirmohamed1
1University of Liverpool, Liverpool, United Kingdom; 2Chang Gung Memorial Hospital, Taipei, Taiwan
O2 Hypersensitivity reactions to beta-lactams, does the t cell recognition pattern influence the clinical picture?
Natascha Wuillemin, Dolores Dina, Klara K. Eriksson, Daniel Yerly
University Hospital Bern, Bern, Switzerland
O3 Specific binding characteristics of HLA alleles associated with nevirapine hypersensitivity
Rebecca Pavlos1, Elizabeth Mckinnin1, David Ostrov2, Bjoern Peters3, Soren Buus4, David Koelle5, Abha Chopra1, Craig Rive1, Alec Redwood1, Susana Restrepo6, Austin Bracey6, Jing Yuan7, Silvana Gaudieri8, Mary Carrington9, David Haas10, Simon Mallal10, Elizabeth Phillips10
1Murdoch University, Perth, Australia; 2University of Florida, Gainesville, USA; 3La Jolla Institute for Allergy and Immunology, La Jolla, USA; 4University of Copenhagen, Copenhagen, Denmark; 5University of Washington, Seattle, USA; 6Univesrity of Florida, Gainesville, USA; 7Boehringer Ingelheim Inc, Ridgefield, USA; 8Univesrity of Western Australia, Perth, Australia; 9Ragon Insitute, Cambridge, USA; 10Vanderbilt University, Nashville, USA
O4 Do we need to measure total ige for the interpretation of analytical results of ImmunoCAP dnd 3gAllergy specific IgE?
Douwe De Boer1, Paul Menheere1, Chris Nieuwhof2, Judith Bons1
1Central Diagnostic Laboratory, MUMC+, Maastricht, The Netherlands; 2Internal Medicine, MUMC+, Maastricht, The Netherlands
O5 Neutrophil activation in systemic anaphylaxis: results from the multicentric NASA Study
Friederike Jonsson1, Luc De Chaisemartin2, Vanessa Granger2, Caitlin Gillis1, Aurelie Gouel1, Catherine Neukirch2, Fadia Dib2, Pascale Roland Nicaise2, Dan Longrois2, Florence Tubach2, Sylvie Martin2, Pierre Bruhns1, NASA Study Group3
1Institut Pasteur, France, France; 2Hopital Bichat, France, France; 3Institut Pasteur & Hopital Bichat, France, France
O6 Purpuric drug eruptions due to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small-cell lung cancer (NSCLC): a clinic-pathological study of 32 cases
Kai-Lung Chen1, Shu-Ling Liao1, Yi-Shuan Sheen1, Yung-Tsu Cho1, Che-Wen Yang1, Jau-Yu Liau2, Chia-Yu Chu1
1Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, Taipei, Taiwan; 2Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, Taipei, Taiwan
Poster Presentations: Poster Walk 1—Anaphylaxis (P01–P09)
P1 Anaphylactic reactions during anaesthesia and the perioperative period
Rita Aguiar, Anabela Lopes, Natália Fernandes, Leonor Viegas, M. A. Pereira-Barbosa
Immunoallergology Department, Hospital de Santa Maria-Centro Hospitalar Lisboa Norte, Lisbon, Portugal
P2 Anaphylaxis to chlorhexidine: is there a cross-reactivity to alexidine?
Antonia Bünter1, Nisha Gupta2, Tatjana Pecaric Petkovic1, Nicole Wirth1, Werner J. Pichler1, Oliver Hausmann3
1ADR-AC GmbH, Bern, Switzerland; 2Teleflex Incorporated, Bern, Switzerland; 3Dep. of Rheumatology, Immunology and Allergology, University Hospital and University of Bern, Bern, Switzerland
P3 Cefotaxime-induced severe anaphylaxis in a neonate
Mehtap Yazicioglu1, Pinar G. Ozdemir1, Gokce Ciplak2, Ozkan Kaya3
1Trakya University Department of Pediatric Allergy, Edirne, Turkey; 2Trakya University Department of Pediatrics, Edirne, Turkey; 3Trakya Hospital, Edirne, Turkey
P4 Clinical features and diagnosis of anaphylaxis resulting from exposure to chlorhexidine
Peter John Cooke
Auckland City Hospital, Auckland, New Zealand
P5 Drug-induced anaphylaxis: five-year single-center survey
Inês Mota, Ângela Gaspar, Filipe Benito-Garcia, Marta Chambel, Mário Morais-Almeida
Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal
P6 Intraoperative severe anaphylactic reaction due to patent blue v dye
Luis Marques, Eva Alcoceba, Silvia Lara
Hospitals Universitaris Santa Maria - Arnau de Vilanova, Lleida, Spain
P7 Kounis syndrome in the setting of anaphylaxis to diclofenac
Leonor Carneiro-Leão, Carmen Botelho, Eunice Dias-Castro, Josefina Cernadas
Serviço de Imunoalergologia, Centro Hospitalar de São João, Porto, Portugal
P8 Perioperative anaphylaxis audit: Royal Melbourne Hospital
Katherine Nicholls1, William Lay2, Olivia Smith2, Christine Collins1, Gary Unglik1, Kymble Spriggs1, Priscilla Auyeung1, Jeremy McComish1, Jo A. Douglass1
1Department of Immunology and Allergy, The Royal Melbourne Hospital, Parkville, Australia; 2Department of Medicine, University of Melbourne, Parkville, Australia
P9 Recurrent peri-operative anaphylaxis: a perfect storm
Jonny G. Peter, Paul Potter
University of Cape Town, Cape Town, South Africa
Poster Walk 2: DH regions and patient groups (P10–P19)
P10 A rare presentation of amoxicillin allergy in a young child
Fabrícia Carolino, Eunice Dias De Castro, Josefina R. Cernadas
Serviço de Imunoalergologia, Centro Hospitalar São João E.P.E., Porto, Portugal
P11 Adverse drug reactions in children: antibiotics or virus?
Ana Sofia Moreira1, Carmo Abreu2, Eva Gomes2
1Centro Hospitalar Vila Nova Gaia e Espinho, Vila Nova Gaia, Portugal; 2Centro Hospitalar do Porto, Porto, Portugal
P12 Allergic reactions in invasive medical procedures
Bárbara Kong Cardoso, Elza Tomaz, Sara Correia, Filipe Inácio
Hospital de S.Bernardo - Centro Hospitalar de Setúbal, Setúbal, Portugal
P13 Antibiotic allergy in children: room for improvement
Annabelle Arnold1, Natasha Bear2, Kristina Rueter3, Grace Gong4, Michael O’Sullivan5, Saravanan Muthusamy1, Valerie Noble1, Michaela Lucas6
1Department of Immunology, Princess Margaret Hospital, Perth, Australia; 2Telethon Kids Institute, Department of Clinical Research and Education, Princess Margaret Hospital, Perth, Australia; 3Department of Immunology, Department of Clinical Research and Education, Princess Margaret Hospital, Telethon Kids Institute, Perth, Australia; 4Department of Immunology, PathWest Laboratory Medicine WA, Princess Margaret Hospital, Perth, Australia; 5Department of Immunology, Princess Margaret Hospital, PathWest Laboratory Medicine WA, Fiona Stanley Hospital, School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia; 6Department of Immunology, Princess Margaret Hospital, Sir Charles Gairdner Hospital, PathWest Laboratory Medicine WA, School of Medicine and Pharmacology, School of Pathology and Laboratory Medicine, University of Western Australia, Institute of Immunology and Infectious Diseases, Murdoch University, Perth, Australia
P14 Drug hypersensitivity reactions in children and results of diagnostic evaluation
Neringa Buterleviciute, Odilija Rudzeviciene
Vilnius University Faculty of Medicine Centre of Children Pulmonology and Allergology, Vilnius, Lithuania
P15 Nonimmediate cutaneous drug reactions in children: are skin tests required?
Ana Sofia Moreira1, Carmo Abreu2, Eva Gomes2
1Centro Hospitalar Vila Nova Gaia e Espinho, Vila Nova Gaia, Portugal; 2Centro Hospitalar do Porto, Porto, Portugal
P16 Pediatric patients with a history of penicillin allergy and a positive penicillin skin test may not be at an increased risk for multiple drug allergies
Sara May1, Thanai Pongdee2, Miguel Park3
1University of Nebraska Medical Center, Omaha, USA; 2Mayo Clinic, Jacksonville, USA; 3Mayo Clinic, Rochester, USA
P17 Proved hypersensitivity to drugs according data of Vilnius University Hospital Santariskiu Klinikos
Linas Griguola1, Arturas Vinikovas1, Simona Kašinskaite2, Violeta Kvedariene2
1Vilnius University, Faculty of Medicine, Vilnius, Lithuania; 2Center of Pulmonology and Allergology, Clinic of Infectious, Chest Diseases, Dermatology and Allergology, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania
P18 Self-reported prevalence of drug hypersensitivity reactions among students in Celal Bayar University, Turkey
Ayse Aktas, Suheyla Rahman, Huseyin Elbi, Beyhan Cengiz Ozyurt
Celal Bayar University, Manisa, Turkey
P19 Severe drug hypersensitivity reactions in pediatric age
Ozlem Cavkaytar, Betul Karaatmaca, Pinar Gur Cetinkaya, Saliha Esenboga, Umit M. Sahiner, Bulent E. Sekerel, Ozge Soyer
Hacettepe University School of Medicine Department of Pediatric Allergy, Ankara, Turkey
Poster Walk 3: Desensitisation (P20–P28)
P20 A protocol for desensitisation to valaciclovir
Celia Zubrinich, Bianca Tong, Mittal Patel, Michelle Giles, Robyn O’Hehir, Robert Puy
Alfred Health, Melbourne, Australia
P21 A rare case of desensitization to modafinil
Josefina Cernadas, Luís Amaral, Fabrícia Carolino
Serviço de Imunoalergologia, Centro Hospitalar de São João E.P.E., Porto, Portugal
P22 A sixteen-day desensitization protocol in delayed type hypersensitivity reactions to oral drugs
Semra Demir, Asli Gelincik, Muge Olgac, Raif Caskun, Derya Unal, Bahauddin Colakoglu, Suna Buyukozturk
Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
P23 Desensitization to intravenous etoposide using a 12 and a 13-step protocol. Two cases report
Olga Vega Matute1, Amalia Bernad1, Gabriel Gastaminza1, Roselle Madamba1, Carlos Lacasa2, M. J. Goikoetxea1, Carmen D’Amelio1, Jose Rifón3, Nicolas Martínez3, Marta Ferrer1
1Departament of Allergy and Immunology Clínica Universidad de Navarra, Pamplona, Spain; 2Department of Pharmacy Clínica Universidad de Navarra, Pamplona, Spain; 3Departament of Hematology Clínica Universidad de Navarra, Pamplona, Spain
P24 Drug desensitisation in oncology: the experience of an immunoallergology department for 5 years
Carmelita Ribeiro1, Emília Faria1, Cristina Frutuoso2, Anabela Barros2, Rosário Lebre2, Alice Pego2, Ana Todo Bom1
1Allergy and Clinical Immunology Department, Coimbra University Hospital Center, Coimbra, Portugal; 2Oncology Department, Coimbra University Hospital Center, Coimbra, Portugal
P25 Filgrastim anaphylaxis: a successful desensitization protocol
Luis Amaral, Josefina Cernadas
Serviço de Imunoalergologia, Centro Hospitalar de São João E.P.E., Porto, Portugal
P26 Galsulfase hypersensitivity and desensitization of a mucopolysaccharidosis VI patient
Luis Felipe Ensina, Carolina Aranda, Ines Camelo Nunes, Ana Maria Martins, Dirceu Solé
Federal University of São Paulo, São Paulo, Brazil
P27 Rapid drug desensitization with biologicals: one-center experience with four biologicals
Sevim Bavbek, Resat Kendirlinan, Pamir Çerçi, Seda Tutluer, Sadan Soyyigit, Zeynep Çelebi Sözener, Ömür Aydin, Reyhan Gümüsburun
Ankara University, Ankara, Turkey
P28 Successful desensitization to a high dose of methotrexate in a delayed type hypersensitivity reaction
Josefina Cernadas1, Leonor Carneiro-Leão1, Fabrícia Carolino1, Marta Almeida2
1Serviço de Imunoalergologia, Centro Hospitalar de São João, Porto, Portugal; 2Serviço de Pediatria, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal
Poster Walk 4: SJS (P29–P38)
P29 Assessment of impact of infection on drug-induced severe cutaneous adverse reactions and rhabdomyolysis using the Japanese adverse drug event report database
Kimie Sai1, Takuya Imatoh1, Ryosuke Nakamura1, Chisato Fukazawa2, Yasushi Hinomura2, Yoshiro Saito1
1National Institute of Health Sciences, Tokyo, Japan; 2Japan Pharmaceutical Information Center, Tokyo, Japan
P30 Characterization of erythema multiforme and severe cutaneous adverse reactions hospitalizations
Bernardo Sousa-Pinto, Cláudia Correia, Lídia Gomes, Sara Gil-Mata, Luís Araújo, Luís Delgado
Immunology Laboratory - Basic and Clinical Immunology, Faculty of Medicine, Porto, Portugal
P31 Effects of infection on incidence/severity of SJS/TEN and myopathy in Japanese cases analyzed by voluntary case reports
Ryosuke Nakamura1, Kimie Sai1, Takuya Imatoh1, Yoshimi Okamoto-Uchida1, Koji Kajinami2, Kayoko Matsunaga3, Michiko Aihara4, Yoshiro Saito1
1National Institute of Health Sciences, Tokyo, Japan; 2Kanazawa Medical University, Ishikawa, Japan; 3Fujita Health University, Aichi, Japan; 4Yokohama City University, Kanagawa, Japan
P32 Efficacy of tumor necrosis factor—a antagonists in Stevens–Johnson syndrome and toxic epidermal necrolysis: a randomized controlled trial and immunosuppressive effects evaluation
Chuang-Wei Wang1, Shih-Chi Su1, Shuen-Iu Hung2, Hsin-Chun Ho1, Chih-Hsun Yang1, Wen-Hung Chung1
1Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou And Keelung, Taiwan; 2Department and Institute of Pharmacology, School of Medicine, Infection and Immunity Research Center, National Yang-Ming University, Linkou, Taiwan
P33 Evolution of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe: analysis of 10 years RegiSCAR-Study
Maren Paulmann1, Ariane Dunant2, Maja Mockenhaupt1, Peggy Sekula3, Martin Schumacher3, Sylvia Kardaun4, Luigi Naldi5, Teresa Bellón6, Daniel Creamer7, Cynthia Haddad8, Bruno Sassolas9, Bénédicte Lebrun-Vignes10, Laurence Valeyrie-Allanore8, Jean-Claude Roujeau8
1Dokumentationszentrum schwerer Hautreaktionen, University Medical Center, Freiburg, Germany; 2Department of Biostatistics and Epidemiology Unit, Institut Gustave-Roussy, Villejuif, France; 3Institute of Medical Biometry and Medical Informatics, University Medical Center, Freiburg, Germany; 4Reference Center for Cutaneous Adverse Reactions, University Medical Center, Groningen, The Netherlands; 5Department of Dermatology, Papa Giovanni XXIII Hospital, Bergamo, Italy; 6Institute for Health Research, University Hospital La Paz–IdiPAZ, Madrid, Spain; 7Department of Dermatology, King’s College Hospital, London, United Kingdom; 8Reference Center for Toxic and Autoimmune Blistering Diseases, Hopital Henri Modor, University Paris-Est, Créteil, France; 9Department of Internal Medicine and Respiratory Diseases, Hôpital Cavale Blanche, Brest, France; 10Department of pharmacology, Hôpital Pitié-salpétrière, Paris, France
P34 Long-term sequelae in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis: a 5-year analysis
Maren Paulmann1, Carmen Kremmler1, Peggy Sekula2, Laurence Valeyrie-Allanore3, Luigi Naldi4, Sylvia Kardaun5, Maja Mockenhaupt1
1Dokumentationszentrum schwerer Hautreaktionen, University Medical Center, Freiburg, Germany; 2Institute of Medical Biometry and Medical Informatics, University Medical Center, Freiburg, Germany; 3Reference Center for Toxic and Autoimmune Blistering Diseases, Hopital Henri Modor, University Paris-Est, Créteil, France; 4Department of Dermatology, Papa Giovanni XXIII Hospital, Bergamo, Italy; 5Reference Center for Cutaneous Adverse Reactions, University Medical Center, Groningen, The Netherlands
P35 Major emotional complications and decreased health related quality of life among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis
Roni P. Dodiuk-Gad1, Cristina Olteanu2, Anthony Feinstein3, Rena Hashimoto4, Raed Alhusayen4, Sonia Whyte-Croasdaile5, Yaron Finkelstein6, Marjorie Burnett7, Shachar Sade8, Robert Cartotto7, Marc Jeschke7, Neil H. Shear4
1Department of Dermatology, Ha’emek Medical Center, Afula, Israel; 2Faculty of Medicine, University of Toronto, Toronto, Canada; 3Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada; 4Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada; 5SJS and TENS Group Canada-CAST International, Toronto, Canada; 6Paediatric Emergency Medicine, Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Canada; 7Ross Tilley Burn Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; 8Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, Canada
P36 Retrospective analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients: treatment and outcome
Naoko Takamura1, Yumiko Yamane1, Setsuko Matsukura2, Kazuko Nakamura2, Yuko Watanabe1, Yukie Yamaguchi1, Takeshi Kambara2, Zenro Ikezawa1, Michiko Aihara1
1Department of Environmental Immuno-Dermatology## Yokohama City University, Yokohama, Japan; 2Department of Dermatology## Yokohama City University Medical Center, Yokohama, Japan
P37 Severe physical complications among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis
Roni P. Dodiuk-Gad1, Cristina Olteanu2, Rena Hashimoto3, Hall Chew4, Raed Alhusayen3, Sonia Whyte-Croasdaile5, Yaron Finkelstein6, Marjorie Burnett7, Shachar Sade8, Robert Cartotto7, Marc Jeschke7, Neil H. Shear3
1Department of Dermatology, Ha’emek Medical Center, Afula, Israel; 2Faculty of Medicine, University of Toronto, Toronto, Canada; 3Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada; 4Department of Ophthalmology and Vision Sciences, Sunnybrook Health Sciences Centre, Toronto, Canada; 5SJS and TENS Group Canada-CAST International, Toronto, Canada; 6Paediatric Emergency Medicine, Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Canada; 7Ross Tilley Burn Centre, Sunnybrook Health Sciences Centre, Toronto, Canada; 8Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, Canada
P38 Stevens–Johnson syndrome/toxic epidermal necrolysis combined with haemophagocytic lymphohistiocytosis: a case report
Brittany Knezevic1, Una Nic Ionmhain1, Allison Barraclough1, Michaela Lucas2, Matthew Anstey1
1Sir Charles Gairdner Hospital, Perth, Australia; 2Pathwest Laboratory Medicine, Queen Elizabeth II Medical Centre, Perth, Australia
Poster Walk 5: Other organs/unexpected immune reactions (P39–P47)
P39 A case report of patient with anti-tuberculosis drug-related severe liver failure
Toru Usui1, Xiaoli Meng1, John Farrell1, Paul Whitaker2, John Watson2, Neil French1, Kevin Park1, Dean Naisbitt1
1MRC Centre for Drug Safety Science, Dept Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom; 2Regional Adult Cystic Fibrosis Unit, St James’s Hospital, Leeds, United Kingdom
P40 Acute interstitial nephritis induced by ibuprofen
Ana Castro Neves, Susana Cadinha, Ana Moreira, J. P. Moreira Da Silva
Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova De Gaia, Portugal
P41 Cetuximab induced acneiform rash—two case reports
Daniela Ledic Drvar1, Sandra Jerkovic Gulin2, Suzana Ljubojevic Hadzavdic1, Romana Ceovic1
1Department of Dermatology and Venereology, University Hospital Center Zagreb and School of Medicine, Zagreb, Croatia; 2Department of Dermatology and Venereology, General Hospital Sibenik, Sibenik, Croatia
P42 Enteropathy associated with losartan
Ana Montoro De Francisco, Talía De Vicente Jiménez, Amelia García Luque, Natalia Rosado David, José Mª Mateos Galván
Hospital Central de la Defesa, IMIDEF, Madrid, Spain
P43 Granuloma annulare after therapy with canakinumab
Razvigor Darlenski
Tokuda Hospital Sofia, Sofia, Bulgaria
P44 Hypersensitivity eosinophilic myocarditis or acute coronary syndrome? Case report
Dario Gulin1, Jozica Sikic1, Jasna Cerkez Habek1, Sandra Jerkovic Gulin2, Edvard Galic1
1University Hospital Sveti Duh, Zagreb, Croatia; 2General Hospital Sibenik, Sibenik, Croatia
P45 Piperacillin-induced immune haemolytic anaemia: a severe and frequent complication of antibiotic treatment in patients with cystic fibrosis
Philip Specht1, Doris Staab1, Beate Mayer2, Jobst Roehmel1
1Division of Cystic Fibrosis, Pediatric Pneumology and Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany; 2Institute for Transfusion Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany
P46 Progesterone triggered pemphigus foliaceus: case report
Sandra Jerkovic Gulin1, Caius Solovan2, Anca Chiriac3
1Department of Dermatology and Venereology, General Hospital Sibenik, Sibenik, Croatia; 2Department of Dermatology, University of Medicine and Pharmacy, Tamisoara, Romania; 3Dermatology Department, Nicolina Medical Centre, Apollonia University, “P.Poni” Research Institute of Macromolecular Chemistry, Iasi, Romania
P47 Ramipril: triggered generalized pustular psoriasis
Paola Djurinec1, Kresimir Kostovic1, Mirna Bradamante1, Sandra Jerkovic Gulin2, Romana Ceovic1
1Department of Dermatology and Venereology, University Hospital Center Zagreb and School of Medicine Zagreb, Zagreb, Croatia; 2Department of Dermatology and Venereology, General Hospital Sibenik, Sibenik, Croatia
Poster Walk 6: NSAIDs (P48–P56)
P48 Aspirin desensitization in cardiovascular disease—Portuguese experience
Jose Pedro Almeida1, Joana Caiado1, Elisa Pedro1, Pedro Canas Da Silva2, Manuel Pereira Barbosa1
1Immunoallergology Department, Centro Hospitalar Lisboa Norte/Hospital Santa Maria, Lisbon, Portugal; 2Cardiology Department, Centro Hospitalar Lisboa Norte/Hospital Santa Maria, Lisbon, Portugal
P49 Asthma and/or rhinitis to NSAIDs with good tolerance to ASA
Gador Bogas1, Natalia Blanca-López2, Diana Pérez-Alzate2, Inmaculada Doña1, José Augusto Agúndez3, Elena García-Martín3, José Antonio Cornejo-García4, Cristobalina Mayorga4, María José Torres1, Gabriela Canto2, Miguel Blanca5
1Allergy Unit, IBIMA, Regional University Hospital of Malaga, UMA, Malaga, Spain; 2Allergy Service, Infanta Leonor University Hospital, Madrid, Spain; 3Department of Pharmacology, University of Extremadura, Caceres, Spain; 4Research Laboratory and Allergy Unit, IBIMA, Regional University Hospital of Malaga, UMA, Malaga, Spain; 5Allergy Unit, IBIMA, Regional University Hospital of Malaga, UMA, Malaga, Spain
P50 Clinical characteristics of 196 patients with non-steroidal anti-inflammatory drug (NSAIDs) hypersensitivity
Sengül Aksakal1, Aytül Zerrin Sin2, Zeynep Peker Koç2, Fatma Düsünür Günsen2, Ömür Ardeniz2, Emine Nihal Mete Gökmen2, Okan Gülbahar2, Ali Kokuludag2
1Karadeniz Technical University Medical Faculty Department of Clinical Immunology, Trabzon, Turkey; 2Ege University Medical Faculty Department of Allergy and Clinical Immunology, Izmir, Turkey
P51 Development of immediate hypersensitivity to several NSAIDs maintaining good tolerance to ASA
Natalia Pérez-Sánchez1, Natalia Blanca-López2, Diana Pérez-Alzate2, Gador Bogas1, Inmaculada Doña1, María Salas1, María José Torres1, Miguel Blanca1, Gabriela Canto2
1Allergy Unit, Malaga Regional University Hospital-IBIMA, Malaga, Spain; 2Allergy Service, Infanta Leonor Hospital, Madrid, Spain
P52 Diagnosis of hypersensitivity reactions to paracetamol in a large serie of cases
Inmaculada Doña1, Maria Salas1, Francisca Gomez1, Natalia Blanca-Lopez2, Diana Perez-Alzate2, Gador Bogas3, Esther Barrionuevo1, Maria Jose Torres1, Inmaculada Andreu4, Miguel Ángel Miranda4, Gabriela Canto2, Miguel Blanca1
1Regional Hospital of Málaga-IBIMA, Málaga, Spain; 2Infanta Leonor Hospital, Madrid, Spain; 3Regional Hospital of Málaga, Málaga, Spain; 4Dpto. Química/Instituto de Tecnología Química –UPV-CSIC, Valencia, Spain
P53 Hypersensitivity to paracetamol according to the new classification of hypersensitivity to NSAIDs
Gabija Didžiokaite1, Olesia Gaidej2, Simona Kašinskaite3, Violeta Kvedariene3
1Vilnius University, Faculty of Medicine, Vilnius, Lithuania; 2Vilnius University Hospital Santariskiu Klinikos, Centre of Internal Medicine, Vilnius, Lithuania; 3Center of Pulmonology and Allergology, Clinic of Infectious, Chest diseases, Dermatology and Allergology, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania
P54 Ibuprofen and other aryl propionic derivates can induce immediate selective hypersensitivity responses
Diana Perez-Alzate1, Natalia Blanca-López1, Maria Isabel Garcimartin1, Inmaculada Doña2, Maria Luisa Somoza1, Cristobalina Mayorga3, Maria Jose Torres4, Gador Bojas2, Jose Antonio Cornejo-Garcia3, Maria Gabriela Canto1, Miguel Blanca5
1Allergy Unit, Infanta Leonor University Hospital, Madrid, Spain; 2Allergy Unit, Regional University Hospital of Malaga, Malaga, Spain; 3Research Laboratory and Allergy Unit, IBIMA, Regional University Hospital of Malaga, Malaga, Spain; 4Allergy Unit, Regional University Hospital of Malaga, Madrid, Spain; 5Allergy Unit, Regional University Hospital of Malaga, Malaga, Spain, Malaga, Spain
P55 Subjects developing immediate responses to several NSAIDs can be selective with good tolerance to ASA
Natalia Blanca-Lopez1, Diana Pérez-Alzate1, Francisco Javier Ruano Perez1, Inmaculada Doña2, Maria Luisa Somoza1, Inmaculada Andreu3, Miguel Angel Miranda3, Cristobalina Mayorga4, Maria Jose Torres2, Jose Antonio Cornejo-Garcia4, Miguel Blanca2, Maria Gabriela Canto1
1Allergy Unit, Infanta Leonor University Hospital, Madrid, Spain; 2Allergy Unit, Regional University Hospital of Malaga, Malaga, Spain; 3Universidad Politécnica de Valencia, Valencia, Spain; 4Research Laboratory and Allergy Unit, IBIMA, Regional University Hospital of Malaga, UMA, Malaga, Spain
P56 Utility of low-dose oral aspirin challenges for diagnosis of aspirin exacerbated respiratory disease
Elina Jerschow1, Teresa Pelletier2, Zhen Ren3, Golda Hudes4, Marek Sanak5, Esperanza Morales6, Victor Schuster1, Simon D. Spivack4, David Rosenstreich7
1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, USA; 2Albert Einstein College of Medicine, Bronx, USA; 3Jacobi Medical Center, NY, USA; 4Albert Einstein College of Medicine/Montefiore Medical Center, NY, USA; 5Jagiellonian University Medical College, Bronx, Poland; 6Ferkauf Graduate School of Psychology at Yeshiva University, NY, USA; 7Albert Einstein College of Medicine/Montefiore Medical Center, Krakow, USA
Poster Walk 7: NSAID 2 (P57–P65)
P57 Alternate regulation of cyclooxygenase-2 (COX-2) MRNA expression may predispose patients to aspirin-induced exacerbations
Renato Erzen, Mira Silar, Nissera Bajrovic, Matija Rijavec, Mihaela Zidarn, Peter Korosec
University Hospital for Respiratory Diseases and Allergy Golnik, Golnik, Slovenia
P58 Anaphylaxis to diclofenac: what about the underlying mechanism?
Leonor Carneiro-Leão, Fabrícia Carolino, Luís Amaral, Carmen Botelho, Eunice Dias-Castro, Josefina Cernadas
Serviço de Imunoalergologia, Centro Hospitalar de São João, Porto, Portugal
P59 COX-2 inhibitors: are they always a safe alternative in hypersensitivity to nonsteroidal anti-inflammatory drugs?
Luis Amaral, Fabricia Carolino, Eunice Castro, Josefina Cernadas
Serviço de Imunoalergologia, Centro Hospitalar de São João E.P.E., Porto, Portugal
P60 Management of patients with history of NSAIDs reactions prior to coronary angioplasty
Mona Al-Ahmad1, Tito Rodriguez2
1Microbiology Department, Faculty of Medicine, Kuwait University, Kuwait, Kuwait; 2Al Rashed Allergy Center, Kuwait, Kuwait
P61 Oral drug challenge with non-steroidal anti-inflammatory drug under spirometric control: clinical series of 110 patients
João Pedro Azevedo, Emília Faria, Beatriz Tavares, Frederico Regateiro, Ana Todo-Bom
Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
P62 Prevalence and incidence of analgesic hypersensitivity reactions in Colombia
Pablo Andrés Miranda1, Bautista De La Cruz Hoyos2
1Universidad Nacional de Colombia, Cartagena, Colombia; 2Centro de Especialistas Santo Domingo - Alergologia, Cartagena, Colombia
2010 % (n) | 2011 % (n) | 2012 % (n) | 2013 % (n) | 2014 % (n) | |
---|---|---|---|---|---|
Prevalence AHR Colombia
Cases per million | |||||
1–5 años | 0.4 (1) | 5.1 (17) | 2.4 (9) | 5.2 (17) | 3.8 (13) |
6–9 años | 5.4 (15) | 6.9 (23) | 4 (15) | 5.2 (17) | 3.2 (11) |
10–14 años | 8 (22) | 6.3 (21) | 9.2 (35) | 10.8 (35) | 12.1 (42) |
15–18 años | 8.3 (23) | 6.9 (23) | 7.4 (28) | 7.7 (25) | 10.8 (37) |
19–26 años | 14.9 (41) | 13.9 (46) | 19.8 (75) | 18.8 (61) | 16.8 (58) |
27–44 años | 34.8 (96) | 32 (106) | 29.8 (113) | 26.2 (85) | 27.7 (96) |
45–59 años | 19.2 (53) | 19 (63) | 16.4 (62) | 16.6 (54) | 14.5 (50) |
>60 años | 9.1 (25) | 9.7 (32) | 11.1 (42) | 9.5 (31) | 11.3 (39) |
Total | 100 (276) | 100 (331) | 100 (379) | 100 (325) | 100 (346) |
Incidence AHR Colombia
Cases per million | |||||
1–5 años | 0 (0) | 0 (0) | 0 (0) | 2.5 (1) | 8.2 (4) |
6–9 años | 5.4 (3) | 0 (0) | 2.4 (1) | 5 (2) | 10.2 (5) |
10–14 años | 8 (4) | 9.3 (5) | 9.5 (4) | 2.5 (1) | 10.2 (5) |
15–18 años | 8.3 (2) | 7.4 (4) | 7.1 (3) | 10 (4) | 18.4 (9) |
19–26 años | 14.9 (4) | 20.4 (11) | 21.4 (9) | 22.5 (9) | 20.4 (10) |
27–44 años | 34.8 (10) | 35.2 (19) | 26.2 (11) | 25 (10) | 16.3 (8) |
45–59 años | 19.2 (8) | 18.5 (10) | 23.8 (10) | 22.5 (9) | 8.2 (4) |
>60 años | 9.1 (7) | 9.3 (5) | 9.5 (4) | 10 (4) | 8.2 (4) |
Total | 100 (38) | 100 (54) | 100 (42) | 100 (40) | 100 (49) |
P63 Recent endoscopic sinus surgery lessens reactions during aspirin challenge in patients with aspirin exacerbated respiratory disease
Teresa Pelletier1, Waleed Abuzeid2, Nadeem Akbar2, Marc Gibber2, Marvin Fried2, Weiguo Han1, Taha Keskin2, Robert Tamayev2, Golda Hudes2, Simon D. Spivack2, David Rosenstreich2, Elina Jerschow2
1Albert Einstein College of Medicine, Bronx, USA; 2Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, USA
P64 Safe use of imidazole salycilate in a case of multiple NSAIDs induced urticaria-angioedema
Elisa Boni, Marina Russello, Marina Mauro
Hospital Sant’Anna, Como, Italy
P65 Selective hypersensitivity reactions to ibuprofen—seven years experience
Marta Ferreira Neto
CHLN-HSM, Lisbon, Portugal
Poster Walk 8: Epidemiological methods (P66–P72)
P66 Allopurinol hypersensitivity: a 7-year review
Lise Brosseron, Daniela Malheiro, Susana Cadinha, Patrícia Barreira, J. P. Moreira Da Silva
Centro Hospitalar Vila Nova de Gaia/Espinho, EPE, Vila Nova De Gaia, Portugal
P67 Antibiotic allergy labelling is associated with increased hospital readmission rates in Australia
Brittany Knezevic1, Dustin Sprigg1, Michelle Trevenen2, Jason Seet1, Jason Trubiano3, William Smith4, Yogesh Jeelall2, Sandra Vale5, Richard Loh6, Andrew Mclean-Tooke7, Michaela Lucas7
1Sir Charles Gairdner Hospital, Perth, Australia; 2The University of Western Australia, Perth, Australia; 3Austin Health, Melbourne, Australia; 4Royal Adelaide Hospital, Adelaide, Australia; 5Australian Society of Clinical Immunology and Allergy, Balgowlah, Australia; 6Princess Margaret Hospital, Perth, Australia; 7Pathwest Laboratory Medicine, Queen Elizabeth II Medical Centre, Perth, Australia
P68 Experts’ opinions on severe cutaneous adverse drug reactions-report of a survey from the 9th international congress on cutaneous adverse drug reactions 2015
Roni P. Dodiuk-Gad1, Cristina Olteanu2, Wen-Hung Chung3, Neil H. Shear4
1Department of Dermatology, Ha’emek Medical Center, Afula, Israel; 2Faculty of Medicine, University of Toronto, Toronto, Canada; 3Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospitals, Taipei, Taiwan; 4Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Linkou, Canada
P69 HLA-A*31-positive AGEP with carbamazepine use and other severe cutaneous adverse drug reactions (SCARs) detected by electronic medical records screening
Sabine Müller1, Ursula Amstutz2, Lukas Jörg3, Nikhil Yawalkar4, Stephan Krähenbühl1
1Department of Clinical Pharmacology and Regional Pharmacovigilance Center, Inselspital, University Hospital Bern, Bern, Switzerland; 2University Institute of Clinical Chemistry, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland; 3Department of Rheumatology, Clinical Immunology and Allergology, Inselspital, University Hospital Bern, Bern, Switzerland; 4Department of Dermatology, Inselspital, University Hospital Bern, Bern, Switzerland
P70 Patients with suspected drug allergy: a specific psychological profile?
Eunice Dias-Castro1, Ana Leblanc1, Laura Ribeiro2, Josefina R. Cernadas1
1Allergy and Clinical Immunology Department, Centro Hospitalar S. João EPE, Porto, Portugal; 2Biochemistry Department, Medical Education and Simulation Department, Faculty of Medicine, University of Porto, Porto, Portugal
P71 Use of an electronic device and a computerized mathematic algorithm to detect the allergic drug reactions through the analysis of heart rate variability
Arantza Vega1, Raquel Gutierrez Rivas2, Ana Alonso1, Juan Maria Beitia1, Belén Mateo1, Remedios Cárdenas1, Juan Jesus Garcia-Dominguez2
1Hospital Universitario de Guadalajara, Guadalajara, Spain; 2Universidad de Alcalá, Alcalá De Henares, Spain
P72 Variation in ERAP influences risk for HLA-B*57:01 positive abacavir hypersensitivity
Rebecca Pavlos1, Kaija Strautins1, Ian James1, Simon Mallal2, Alec Redwood1, Elizabeth Phillips2
1Murdoch University, Perth, Australia; 2Vanderbilt University, Nashville, USA
Poster Walk 9: DRESS/AGEP (P73–P81)
P73 A clinical case of DRESS syndrome in a child after administration of amoxicillin-clavulanic acid
Rita Aguiar1, Anabela Lopes1, Ana Neves2, Maria Do Céu Machado2, M. A. Pereira-Barbosa1
1Immunoallergology Department, Hospital de Santa Maria-Centro Hospitalar Lisboa Norte, Lisbon, Portugal; 2Pediatrics Department, Hospital de Santa Maria-Centro Hospitalar Lisboa Norte, Lisbon, Portugal
P74 Acute generalized exanthematous pustulosis (AGEP) induced by mesalazine, reliable and oftenly used drug to treat inflammatory bowel disease
Ceyda Tunakan Dalgiç, Emine Nihal Mete Gökmen, Fatma Düsünür Günsen, Gökten Bulut, Fatma Ömür Ardeniz, Okan Gülbahar, Ali Kokuludag, Aytül Zerrin Sin
Ege University Medical Faculty, Department of Allergy and Clinical Immunology, Izmir, Turkey
P75 Changes of blood plasmacytoid dendritic cells, myeloid dendritic cells, and basophils during the acute stage of drug reaction with eosinophilia and systemic symptoms (DRESS) and other drug eruptions
Shao-Hsuan Hsu, Yung-Tsu Cho, Che-Wen Yang, Kai-Lung Chen, Chia-Yu Chu
Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
P76 Characterization of isoniazid/rifampicin-specific t-cell responses in patients with DRESS syndrome
Young-Min Ye1, Gyu-Young Hur2, Hae-Sim Park1, Seung-Hyun Kim1
1Department of Allergy & Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea; 2Department of Internal medicine, College of Medicine, Korea University, Seoul, South Korea
P77 DRESS syndrome secondary to sulfasalazine with delayed TEN: a case presentation
Syed Ali1, Michaela Lucas2, Peter N. Hollingsworth3, Andrew P. C. Mclean-Tooke3
1Department of Immunology, Perth, Australia; 2Department of Immunology, Pathwest; QE2 Medical Centre; SMP, PALM, UWA; IIID, Murdoch University, Perth, Australia; 3Department of Immunology, Pathwest; QE2 Medical Centre, Perth, Australia
P78 Drug rash with eosinophilia and systemic symptoms (DRESS) features according to the culprit drug
Zohra Chadly, Nadia Ben Fredj, Karim Aouam, Haifa Ben Romdhane, Naceur A. Boughattas, Amel Chaabane
Faculty of Medicine/University Hospital/University of Monastir, Monastir, Tunisia
P79 Drug reaction with eosinophilia and systemic symptoms induced by allopurinol: not always easy to diagnose
Marina Lluncor Salazar1, Beatriz Pola1, Ana Fiandor2, Teresa Bellón3, Elena Ramírez4, Javier Domínguez Ortega2, Santiago Quirce5, Rosario Cabañas2
1Allergy Department, La Paz Hospital Institute for Health Research (IdiPAZ), Madrid, Spain; 2Allergy Department, La Paz Hospital Institute for Health Research (IdiPAZ), Consorcio Piel en RED, Madrid, Spain; 3Immunology Department, La Paz Hospital Institute for Health Research (IdiPAZ), Consorcio Piel en RED, Madrid, Spain; 4Department of Clinical Pharmacology, Hospital La Paz Health Research Institute (IdiPAZ), School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain. Consorcio Piel en RED, Madrid, Spain; 5Allergy Department, La Paz Hospital Institute for Health Research (IdiPAZ), Madrid, Spain
P80 Drug reaction with eosinophilia and systemic symptoms syndrome induced by two drugs simultaneously: a case report
Krasimira Baynova, Marina Labella, Manuel Prados
HUVR Seville, Seville, Spain
P81 The drug reaction with eosinophilia and systemic symptoms (DRESS) induced by the second-line antituberculosis drugs and Epstein–Barr virus infection
Agne Ramonaite, Ieva Bajoriuniene, Brigita Sitkauskiene, Raimundas Sakalauskas
Department of Pulmonology and Immunology, Lithuanian University of Health Sciences, Kaunas, Lithuania
Poster Walk 10: Miscellaneous drug hypersensitivity (P82–P91)
P82 A case of cycloserine-induced lichenoid drug eruption confirmed with a lymphocatye transformation test
Jae-Woo Kwon1, Shinyoung Park2
1Department of Allergy and Clinical Immunology, Kangwon National University School of Medicine, Chuncheon, Korea; 2The Research Department, Kangwon Regional Cancer Center, Kangwon National University Hospital, Chuncheon, Korea
P83 Allergic reaction to topical eye drops: 5 years’ retrospective study in a drug allergy unit
Diana Silva1, Leonor Carneiro Leão1, Fabricia Carolino2, Eunice Castro2, Josefina Cernadas2
1Allergy and Clinical Immunology Department, São João Medical Center; Laboratory of Basic & Clinical Immunology, Faculty of Medicine, Porto University, Porto, Portugal; 2Allergy and Clinical Immunology Department, São João Medical Center, Porto, Portugal
P84 Allergy to heparins
Diana Perez-Alzate, Natalia Blanca-López, Maria Luisa Somoza Alvarez, Maria Garcimartin, Maria Vazquez De La Torre, Francisco Javier Ruano Pérez, Elisa Haroun, Gabriela Canto Diez
Hospital Universitario Infanta Leonor, Madrid, Spain
P85 Allopurinol-induced adverse drug reactions
Katinka Ónodi-Nagy1, Ágnes Kinyó2, Lajos Kemény1, Zsuzsanna Bata-Csörgo1
1Department of Dermatology and Allergology, Szeged, Hungary; 2Department of Dermatology, Venereology and Oncodermatology, Pécs, Hungary
P86 Analysis of a population with immediate hypersensitivity to corticosteroids: an 11 year review
Joana Sofia Pita1, Emília Faria1, Rosa Anita Fernandes1, Ana Moura1, Nuno Sousa2, Carmelita Ribeiro1, Carlos Loureiro1, Ana Todo Bom1
1Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; 2Centro Hospitalar de Leiria, Leiria, Portugal
P87 Anaphylaxis against mivacurium in a 12-months old boy at first-time exposure
Wolfgang Pfützner
Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany
P88 Antihistamine-exacerbated chronic spontaneous urticaria: a paradox?
Nadine Marrouche, Clive Grattan
Norfolk and Norwich University Hospital, Norwich, United Kingdom
P89 Anti-osteoporotic agents-induced cutaneous adverse drug reactions in Asians
Yu-En Chen1, Chun-Bing Chen2, Wen-Hung Chung2, Yu-Ping Hsiao3, Chia-Yu Chu4
1College of Medicine, Chung Shan Medical University Hospital and Chung Shan Medical University, Taichung, Taiwan; 2Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospitals, Linkou, Taipei, Keelung, Taiwan; 3Department of Dermatology, Chung Shan Medical University Hospital and Chung Shan Medical University College of Medicine, Taichung, Taiwan; 4Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
Region | Asia | Europe | |
---|---|---|---|
Case series | This study | Tan et al. [1]/Lee et al. [2] | Cacoub et al. [3] |
Country | Taiwan and Hong Kong | Singapore | France etc. |
Culprit anti-osteoporotic agent | SR1
| SR | SR |
Indication to anti-osteoporotic agent | OPO | PM OPO2
| OPO |
Patients’ profile | |||
Ethnicity | Chinese | Chinese | Caucasian |
Gender | F (83.3) | F (100.0) | F (100.0) |
Average age (year) | 64.7 | 69.5 | 68.7 (in DRESS group) |
No. of SCARs patients | 7 | 2 | 52 |
Phenotype | |||
SJS/TEN3
| |||
Total case no. | 6 (85.7) | 2 (100.0) | 5 (9.6) |
Average latent period (days) | 29.2 | 16 | Not mentioned |
Eye involvementa
| 1 (16.7) | 1 (50) | Not mentioned |
Orogenital involvement | 5 (83.3) | 2 (100.0) | Not mentioned |
DRESS4
| |||
Total case No. | 1 (14.3) | 0 | 47(90.4) |
Average latent period (days) | 90.0 | 0 | 33.5 |
Liver involvementb
| 0 (0) | 0 (0) | 37 (79.0) |
Kidney involvementc
| 0 (0) | 0 (0) | 12 (25.0) |
Eosinophiliad
| 1 (100.0) | 0 (0) | 43 (91.0) |
Clinical sequelae | Nil | Nil | Persistent DRESS symptoms (21.3) and relapse of DRESS (2.0) |
Mortality rate | 0 % | 0 % | 8.5 % (in DRESS group) |